Gilead Sciences Inc Annual Earnings Report
Recently, Gilead Sciences Inc (NASDAQ: GILD) announced their adjusted earnings per share (EPS) for the fourth quarter of 2024, with impressive results coming in at $1.90. This exceeded analysts' expectations, which were set at $1.70.
Annual Sales Growth
The company reported a 6% year-over-year increase in sales, totaling $7.57 billion, surpassing the consensus estimate of $7.14 billion. This growth can be largely attributed to a significant boost in the HIV segment, along with notable increases in oncology and liver disease sales. However, the overall sales figures were somewhat dampened by decreased sales from Veklury (remdesivir).
Sector Performance Highlights
Specifically, HIV sales rose 16% to reach $5.45 billion, spurred by heightened demand, higher prices, and favorable inventory conditions. In particular, sales from Biktarvy rose impressively from $3.12 billion to $3.8 billion, illustrating the strength of their portfolio in the HIV treatment market.
Liver Disease Sales Insights
Turning to liver disease, Gilead noted a 4% increase in sales to $719 million. This uptick was driven by a successful launch of Livdelzi and an increase in demand for HBV/HDV therapies. However, the report did note challenges with hepatitis C virus (HCV) treatments due to a decline in new patient starts.
Dividend Increase
With strong financial performance, Gilead Sciences declared a 2.6% increase in its quarterly cash dividend, which now stands at $0.79 per share, reflecting the company’s commitment to returning value to shareholders.
Future Guidance and Expectations
Looking ahead, Gilead provided updated guidance for 2025, predicting an adjusted EPS in the range of $7.70 to $8.10, outperforming the consensus average of $7.58. They are also projecting total sales between $28.2 billion and $28.6 billion, exceeding expectations.
Lenacapavir Launch Plans
One key highlight in their announcement was the anticipated launch of lenacapavir for HIV prevention (PrEP) targeted for Summer 2025. According to Gilead’s Chairman and CEO, Daniel O'Day, this innovative treatment offers a unique opportunity to broaden access to HIV prevention efforts.
Analyst Upgrades Following Earnings
Following the announcement, Piper Sandler responded positively, increasing their price forecast for Gilead from $105 to $110, while maintaining an Overweight rating. Analysts highlighted the potential impact of the upcoming lenacapavir commercial launch and several other late-stage readouts that could benefit the company.
Positioning in the Market
Goldman Sachs remarked that Gilead is well-positioned for the lenacapavir launch, suggesting that it could solidify the company's standing within the PrEP market. The firm's analysis indicated that Gilead could improve patient adherence rates and stay competitive in the evolving landscape of HIV prevention.
Market Dynamics and Analyst Views
In terms of market dynamics, though there may be challenges in oncology due to competitive pressures affecting other products like Kite and Trodelvy, the landscape for Gilead appears favorable overall. Needham's analyst, Joseph Stringer, emphasized the importance of upcoming significant events, especially the lenacapavir launch and key trial updates for Trodelvy.
Stock Performance Update
As of the latest updates, Gilead's stock showed an impressive increase of 7.73%, trading at $103.57. This uptick reflects the positive reception from investors following the robust earnings report and optimistic guidance for the upcoming year.
Frequently Asked Questions
What are Gilead's recent financial results?
Gilead reported an adjusted EPS of $1.90 for Q4 2024, surpassing expectations. Total sales reached $7.57 billion, a 6% year-over-year increase.
How much did Gilead increase its dividend?
Gilead announced a 2.6% increase in its quarterly cash dividend, now $0.79 per share.
What is the projected launch date for lenacapavir?
Lenacapavir for HIV prevention is anticipated to launch in Summer 2025.
How did analysts respond to Gilead's earnings report?
Analysts, including Piper Sandler and Goldman Sachs, generally responded positively, with increases in price targets due to optimism about future launches.
What are Gilead's future sales expectations?
For 2025, Gilead projects sales between $28.2 billion and $28.6 billion, which exceeds the consensus expectation.
